Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.44 |
| ▸ | CA9 | Q16790 | 15/20 | 0.44 |
| ▸ | CA1 | P00915 | 14/20 | 0.44 |
| ▸ | CA12 | O43570 | 13/20 | 0.44 |
| ▸ | CA7 | P43166 | 4/20 | 0.43 |
| ▸ | CA6 | P23280 | 3/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16180595 | 0.85 | CA2 (0.39) | CA2CA9CA1CA12CA7 | |
| SCHEMBL27828979 | 0.77 | CA12 (0.36) | CA2CA9CA1CA12CA7 | |
| SCHEMBL27821403 | 0.76 | GAA (0.35) | CA2CA9CA1CA12CA7 | |
| SCHEMBL7897251 | 0.75 | MGLL (0.35) | CA2CA9CA1CA12CA14 | |
| SCHEMBL458964 | 0.74 | IDO1 (0.38) | CA2CA12CA4CA5ACA5B | |
| SCHEMBL28861560 | 0.71 | MGLL (0.42) | — | |
| SCHEMBL28919292 | 0.71 | CA2 (0.44) | CA2CA9CA1CA12CA7 | |
| SCHEMBL27957824 | 0.70 | ADRB1 (0.44) | — | |
| SCHEMBL30136182 | 0.70 | ADRB1 (0.43) | — | |
| SCHEMBL28857529 | 0.70 | NCF1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160332959-A1 | FLUORINATED ARYLALKYLAMINOCARBOXAMIDE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-11-17 | — | — | US | disclosed |
| US-9447029-B2 | Fluorinated arylalkylaminocarboxamide derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-09-20 | — | — | US | disclosed |
| EP-2723710-B1 | FLUORINATED ARYLALKYLAMINOCARBOXAMIDE DERIVATIVES | NEWRON PHARM SPA (IT) | 2016-08-10 | — | — | EP | disclosed |
| EP-2791108-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2016-07-27 | — | — | EP | disclosed |
| US-20150291514-A1 | N-Aminosulfonyl Benzamides | PFIZER LIMTED (GB) | 2015-10-15 | — | — | US | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9102621-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-9096558-B2 | N-sulfonylbenzamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-9096500-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-9085517-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| WO-2012004714-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004706-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004743-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010182-A1 | Chemical Compounds | ICAGEN INC. (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2385938-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-8040476-B2 | Display device and method of producing the same | MITSUBISHI ELECTRIC CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | CA2 302/4885CA9 1021/4885CA1 1355/4885 |
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | CA2 240/4885CA9 1290/4885CA1 1368/4885 |
| US-20120010182-A1 | Chemical Compounds | SCN1A, SCN1B, CACNA1E | CA2 226/4885CA9 603/4885CA1 817/4885 |
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | CA2 953/4885CA9 3096/4885CA1 2563/4885 |
| US-20150291514-A1 | N-Aminosulfonyl Benzamides | SCN7A, SCN2B, SCN1B | CA2 473/4885CA9 2416/4885CA1 2481/4885 |
| US-20160332959-A1 | FLUORINATED ARYLALKYLAMINOCARBOXAMIDE DERIVATIVES | CACNA1E, CACNA1B, CACNA1A | CA2 179/4885CA9 1573/4885CA1 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.